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ABSTRACT  
Purpose: Mucosal melanoma is an aggressive malignancy with a poor response to conventional 
therapies. The efficacy and safety of nivolumab (a PD-1 checkpoint inhibitor), alone or 
combined with ipilimumab (a CTLA-4 checkpoint inhibitor), have not been reported in this rare 
melanoma subtype.  
Patients and Methods: Data were pooled from 889 patients who received nivolumab 
monotherapy in clinical studies, including phase III trials; 86 (10%) had mucosal melanoma and 
665 (75%) had cutaneous melanoma. Data were also pooled for patients who received nivolumab 
combined with ipilimumab (n=35, mucosal melanoma; n=326, cutaneous melanoma).   
Results: Among patients who received nivolumab monotherapy, median progression-free 
survival (mPFS) was 3.0 months (95% CI, 2.2 to 5.4 months) and 6.2 months (95% CI, 5.1 to 7.5 
months) for mucosal and cutaneous melanoma, with objective response rates of 23.3% (95% CI, 
14.8% to 33.6%) and 40.9% (95% CI, 37.1% to 44.7%), respectively. In studies of nivolumab 
combined with ipilimumab, mPFS was 5.9 months (95% CI, 2.8 months to not reached) and 11.7 
months (95% CI, 8.9 to 16.7 months) for mucosal and cutaneous melanoma, with objective 
response rates of 37.1% (95% CI, 21.5% to 55.1%) and 60.4% (95% CI, 54.9% to 65.8%), 
respectively. For mucosal and cutaneous melanoma, respectively, the incidence of grade 3 or 4 
treatment-related adverse events was 8.1% and 12.5% for nivolumab monotherapy and was 
40.0% and 54.9% for combination therapy.  
Conclusion: To our knowledge, this is the largest analysis of data for anti-PD-1-based therapy in 
mucosal melanoma to date. Nivolumab combined with ipilimumab appeared to have greater 
efficacy than either agent alone, and although the activity was lower in mucosal melanoma, the 
safety profile was similar between subtypes. 
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INTRODUCTION 
Ipilimumab, which blocks cytotoxic T-lymphocyte antigen-4,1 has demonstrated long-term 
survival in ~20% of patients with advanced melanoma.2 Another immune checkpoint inhibitor, 
nivolumab, blocks the interaction of the programmed death 1 receptor (PD-1) with its ligands, 
PD-L1 and PD-L2.1 In phase III trials, nivolumab monotherapy showed improved overall 
survival (OS) and a greater objective response rate (ORR) versus dacarbazine in untreated 
patients with BRAF wild-type melanoma,3 and a greater ORR versus chemotherapy in melanoma 
patients who progressed on ipilimumab or ipilimumab and a BRAF inhibitor.4 In phase II and III 
clinical trials, nivolumab in combination with ipilimumab improved progression-free survival 
(PFS) and ORR versus ipilimumab alone in treatment-naïve patients with advanced melanoma.5,6          
Several new agents have been approved for the treatment of cutaneous melanoma since 2011, 
including the combination of nivolumab and ipilimumab, yet there is a paucity of  published 
information regarding the efficacy and safety of these agents in other melanoma subtypes. In 
Caucasian populations, the primary sites of melanoma are cutaneous (82%), uveal (8%), acral 
(3%), and mucosal (2%), with ~5% being unknown.7 Mucosal melanomas primarily occur in the 
head and neck region (eg, nasal and oral cavities), followed by the gastrointestinal tract 
(anorectum) and female genital tract (vulva and vagina).8,9 Accordingly, they occur at a higher 
incidence in females than in males.10 Although mucosal melanomas are rare in Caucasian 
populations, accounting for 2% or less of all melanomas,7,10 the incidence has been reported to 
be up to 23% in Chinese populations.11 Prognosis for these patients is poor, with a 5-year 
survival rate less than that reported for cutaneous or uveal melanoma.9 
Mucosal melanoma is a very aggressive subtype that is largely resistant to traditional 
therapies.11,12 A major challenge with mucosal melanoma is that well established protocols for 
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staging and treatment are lacking, and in the absence of discernable signs or symptoms 
recognizable by the patient, diagnosis often occurs at late stages.9 Anatomical location often 
precludes complete surgical resection as negative margins are difficult to achieve.9 Response 
rates with chemotherapy are poor and are generally similar to those observed in cutaneous 
melanoma.13 Patients with mucosal, acral, and chronically sun-damaged melanomas infrequently 
have BRAF mutations, but amplifications or activating mutations in the receptor tyrosine kinase, 
KIT, are common.14,15  While typically of short duration, anti-tumor activity with KIT inhibitors 
such as imatinib has been observed in mucosal melanoma with certain KIT mutations.14,15  
While ipilimumab and anti-PD-1 agents have demonstrated activity in mucosal melanoma, the 
evidence is based on small study populations, retrospective analyses, and single case reports.16-20 
In two retrospective analyses and data from an expanded access program, ipilimumab treatment 
resulted in an ORR of 7% to 12%, median PFS of 2.3 to 4.3 months, and median OS of 6.4 
months in patients with metastatic mucosal melanoma.16,17,18 In a phase II study, 1-year OS rates 
of 38% and 14% were reported for ipilimumab-treated patients with cutaneous (n=83) and 
mucosal (n=7) melanoma, respectively.19 A patient with mucosal melanoma was reported to 
achieve a durable, near-complete response when treated with an anti-PD-1 agent following 
ipilimumab.20 To better understand the benefit of anti-PD-1-based therapy in this melanoma 
subtype, we conducted a pooled analysis of data  from patients with mucosal melanoma who 
received nivolumab alone or combined with ipilimumab in clinical trials.     
PATIENTS AND METHODS   
Study Population  
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Patients included in the current analyses had a confirmed histological diagnosis of unresectable 
stage III or stage IV (advanced) melanoma. Those with primary uveal melanoma were excluded 
from four of the six nivolumab clinical trials from which the data in these analyses were derived, 
but patients with primary mucosal melanoma were eligible to participate in all studies. In these 
studies, M staging of mucosal melanomas was based on cutaneous melanoma criteria. 
Information regarding the exact location of the primary site of mucosal melanomas was not 
collected during the trials.     
Clinical Trials 
Data were pooled from 889 patients with advanced melanoma who had received nivolumab 
monotherapy (3 mg/kg, every 2 weeks until progression or unacceptable toxicity) in one of five 
ongoing clinical trials: (1) a phase I dose-ranging study in previously treated patients (CA209-
003; n=17);21 (2) a phase I biomarker study to evaluate the immunomodulatory effects of 
nivolumab (CA209-038; n=85);22 (3) a phase III trial of nivolumab versus chemotherapy in 
treatment-naïve patients with wild-type  BRAF (CheckMate 066; n=206);3 (4) a phase III trial of 
nivolumab versus chemotherapy in patients who progressed following ipilimumab, or 
ipilimumab and a BRAF inhibitor if positive for a BRAF V600 mutation (CheckMate 037; 
n=268);4 and (5) a phase III trial of nivolumab monotherapy or nivolumab plus ipilimumab 
versus ipilimumab monotherapy in treatment-naïve patients (CheckMate 067; n=313).6  
To evaluate the efficacy and safety of nivolumab combined with ipilimumab in mucosal 
melanoma, data were pooled from CheckMate 067 and an ongoing phase II trial (CheckMate 
069) of nivolumab plus ipilimumab versus ipilimumab alone in treatment-naïve patients.5 Across 
melanoma subtypes, 407 patients (n=313 from CheckMate 067, n=94 from CheckMate 069) had 
received nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) every 3 weeks for up to 4 doses [and 
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following combination therapy, patients could have received nivolumab monotherapy at 3 
mg/kg, every 2 weeks until progression or unacceptable toxicity]; 357 patients had received 
ipilimumab monotherapy (3 mg/kg, every 3 weeks for 4 doses). 
Data Analyses   
For comparisons of patient demographics between subtypes, P values were based on the Chi-
square test for categorical variables and 2-sample t test for continuous variables. Median PFS 
was based on Kaplan-Meier estimates, with two-sided 95% CIs computed using the Brookmeyer 
and Crowley method. Hazard ratios (HRs) and corresponding 95% CIs were estimated using an 
unstratified Cox proportional-hazards model. In an exploratory analysis, P values for 
comparisons of PFS between treatment groups within each subtype were calculated using an 
unstratified log-rank test. Tumor response was assessed using Response Evaluation Criteria in 
Solid Tumors (RECIST) version 1.1 in all studies except CA209-003, in which RECIST version 
1.0 (with modification) was used.3‒6,21,22 The proportion of patients with a confirmed complete or 
partial response (ORR) was calculated for each pooled dataset, with 95% CIs based on the 
Clopper and Pearson method. Kaplan-Meier methodology was used to calculate duration of 
response, defined as the time between the date of first documented objective response and the 
date of first subsequent disease progression or death, whichever occurred first. OS was not 
included in the analyses due to the lack of mature data for most of the studies. No formal 
comparisons were made between subtypes for any efficacy endpoint. 
ORR and PFS were also evaluated in the pooled datasets according to PD-L1 status, which was 
evaluated with a verified immunohistochemical assay using a rabbit monoclonal antihuman 
antibody (clone 28-8) as described previously.23 Each biopsied tissue sample was scored with a 
cutoff of ≥5% or <5% of tumor cells having cell-surface PD-L1 staining of any intensity in a 
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section with at least 100 evaluable tumor cells. Adverse events (AEs) were graded according to 
the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. 
Patients were evaluated for safety if they had received at least one dose of nivolumab 
monotherapy or one dose each of nivolumab and ipilimumab as combination therapy.   
RESULTS  
Patient Characteristics and Treatment  
Among 889 patients who received nivolumab monotherapy, 86 (10%) with mucosal melanoma 
and 665 (75%) with cutaneous melanoma were included in the analyses. For those who received 
nivolumab combined with ipilimumab (n=407), 35 patients (9%) with mucosal melanoma and 
326 (80%) with cutaneous melanoma were included; 36 of 357 patients (10%) with mucosal 
melanoma and 269 (75%) with cutaneous melanoma had received ipilimumab monotherapy. The 
remaining 11-15% of patients within each pooled group were diagnosed with acral melanoma, 
uveal melanoma, or unknown primaries.  
Baseline demographics were balanced between mucosal and cutaneous melanoma subtypes, 
across treatment groups, for age, ECOG performance status, and M stage (Table 1). However, 
relative to cutaneous melanoma, a higher percentage of patients with mucosal melanoma were 
female (P = 0.0035 for nivolumab monotherapy; P = 0.0114 for combination therapy) and a 
lower percentage had tumor  PD-L1 expression ≥5% (P = 0.0071 for nivolumab monotherapy). 
While the differences were not statistically significant, more patients with mucosal melanoma 
had elevated lactate dehydrogenase (LDH) levels. More patients with cutaneous melanoma had a 
BRAF mutation, consistent with the known molecular pathology of this subtype compared with 
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mucosal melanoma. Other genetic abnormalities, such as mutations in c-KIT, were not tested in 
our study population.     
Patients with mucosal melanoma who were treated with nivolumab monotherapy had received a 
median of 7.0 doses (range, 1 to 34), and those with cutaneous melanoma had received a median 
of 11.0 doses (range, 1 to 61). In the combination group, a median of 4.0 doses (range, 1 to 28) 
of nivolumab and 4.0 doses (range, 1 to 4) of ipilimumab were received by patients with mucosal 
melanoma; patients with cutaneous melanoma received similar dosing (nivolumab, median of 4.0 
doses [range, 1 to 39]; ipilimumab, median of 4.0 doses [range, 1 to 4]). Patients treated with 
ipilimumab monotherapy, regardless of melanoma subtype, received a median of 4.0 doses 
(range, 1 to 4). In the three treatment groups, median follow-up times ranged from 6.2 to 8.6 
months for mucosal melanoma and ranged from 10.0 to 11.7 months across melanoma subtypes. 
Efficacy   
Median PFS was 3.0 months (95% CI, 2.2 to 5.4 months), 5.9 months (95% CI, 2.2 to not 
reached), and 2.7 months (95% CI, 2.6 to 2.8 months) for patients with mucosal melanoma who 
received nivolumab monotherapy, combination therapy, and ipilimumab monotherapy, 
respectively (Fig.1A). For patients with cutaneous melanoma, median PFS was 6.2 months (95% 
CI, 5.2 to 7.5 months), 11.7 months (95% CI, 8.9 to 16.7), and 3.9 months (95% CI, 2.9 to 4.4 
months), respectively (Fig.1B). ORR was 23.3% (95% CI, 14.8% to 33.6%), 37.1% (95% CI, 
21.5% to 55.1%), and 8.3% (95% CI, 1.8% to 22.5%) for mucosal melanoma, and was 40.9% 
(95% CI, 37.1% to 44.7%), 60.4% (95% CI, 54.9% to 65.8%), and 21.2% (95% CI, 16.5% to 
26.6%) for cutaneous melanoma, among those who received nivolumab, combination therapy, or 
ipilimumab, respectively (Table 2).      
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Median time to response was similar for both melanoma subtypes, regardless of treatment, and 
median duration of response was not reached in most groups (Table 2). There were ongoing 
responses in 85% of responders who received nivolumab alone or combination therapy 
(Appendix Figure A1). In patients with mucosal melanoma, median reduction in tumor burden in 
the target lesions was -1.4% for nivolumab monotherapy, -34.2% for combination therapy, and 
+28.6% for ipilimumab monotherapy (Figure 2). Subgroup analyses in patients with mucosal 
melanoma suggested improved PFS and higher ORR with nivolumab monotherapy or 
combination therapy versus ipilimumab monotherapy across patient subgroups (Figure 3). 
Moreover, there appeared to be longer PFS and higher ORR across patient subgroups for 
combination therapy compared to nivolumab monotherapy.   
Efficacy by PD-L1 status 
In patients with mucosal melanoma and tumor PD-L1 expression ≥5% (n=32), ORR was 53.3% 
(95% CI, 26.6% to 78.7%), 60.0% (95% CI, 26.2% to 87.8%) and 14.3% (95% CI, 0.4% to 
57.9%) for nivolumab monotherapy, combination therapy, and ipilimumab monotherapy, 
respectively (Appendix Table A1); among patients with PD-L1 expression <5% (n=88), ORR 
was 12.2% (95% CI, 4.6% to 24.8%), 33.3% (95% CI, 13.3% to 59.0%), and 9.5% (95% CI, 
1.2% to 30.4%), respectively. The magnitude of differences in ORR between patients with PD-
L1 expression ≥5% and those with PD-L1 expression <5% were greater for mucosal melanoma 
than for cutaneous melanoma (Appendix Table A1). Median PFS among patients with mucosal 
melanoma and tumor PD-L1 expression ≥5% was 12.2 months (95% CI, 3.0 months to not 
reached) for nivolumab monotherapy, not reached for combination therapy, and 2.8 months 
(95% CI, 2.6 months to not reached) for ipilimumab monotherapy (Appendix Figure A2). 
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Among patients with mucosal melanoma and tumor PD-L1 expression <5%, median PFS ranged 
from 2.2 to 2.8 months across treatment groups (Appendix Figure A2).    
Safety 
Table 3 summarizes the AEs that were considered to be related to study drug treatment in at least 
5% of patients. The types and frequencies of treatment-related AEs were generally similar 
among patients with mucosal and cutaneous melanoma. However, the frequencies of treatment-
related grade 3 or 4 AEs were higher for patients with cutaneous melanoma, particularly for 
those who received combination therapy (54.9% versus 40.0%). In patients with mucosal 
melanoma, the most common treatment-related grade 3 or 4 AEs were diarrhea and rash in those 
who received nivolumab monotherapy, and increased lipase and diarrhea for those who received 
combination therapy. In mucosal and cutaneous melanoma, respectively, the rates of 
discontinuation due to treatment-related AEs of grade 3 or 4 were 2.3% and 3.9% for nivolumab 
monotherapy and were 17.1% and 31.0% for combination therapy. There were no drug-related 
deaths in patients with mucosal or cutaneous melanoma who received nivolumab monotherapy, 
nor in patients with cutaneous melanoma who received combination therapy. One drug-related 
death (2.9%) was reported in a patient with mucosal melanoma who received combination 
therapy. This patient had a history of cardiac disease and died from ventricular arrhythmia 29 
days after the last dose of study drug.    
DISCUSSION  
To our knowledge, this pooled analysis represents the largest report to date of the efficacy and 
safety of an immune checkpoint inhibitor in mucosal melanoma. While relatively small numbers 
of patients with mucosal melanoma were enrolled in individual nivolumab studies, this pooled 
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analysis of data from six clinical studies has allowed for a more rigorous evaluation of anti-PD-
1-based therapy in this subtype. The inclusion of these patients into the clinical trials, and 
exclusion of other melanoma subtypes from most of the studies, likely explains the higher 
incidence of mucosal melanoma in our analyses than is observed in the general population. 
Nivolumab combined with ipilimumab consistently showed a clinically meaningful improvement 
in PFS and ORR compared to either agent alone, with most tumor responses being durable. 
These results were observed across patient subgroups, including those with M1c disease and 
elevated LDH levels. Safety profiles were consistent with those observed in cutaneous 
melanoma.      
Primary mucosal melanomas can arise from virtually any mucosal membrane, with the female 
genital tract being a common site of origin.8,9 In our study population, there was a higher 
percentage of females among patients with mucosal melanoma, versus a higher percentage of 
males in patients with cutaneous melanoma. Mucosal melanomas are considered to be the most 
aggressive of all melanoma subtypes.11 A higher percentage of patients with mucosal melanoma 
in our study had elevated LDH compared to patients with cutaneous melanoma. While no formal 
comparisons were made between subtypes, efficacy outcomes appeared to be poorer in mucosal 
melanoma than in cutaneous melanoma. The exact reasons for the apparent differences in 
response to treatment between these subtypes remain unclear, yet studies have shown distinct 
biological differences among non-cutaneous melanomas and between cutaneous and non-
cutaneous melanomas.8,11,24 These differences include higher ratios of metastasis at diagnosis for 
mucosal and unknown primary melanomas,8 and a different pattern of metastasis for mucosal 
melanomas compared with other subtypes.24 Furthermore, while we did not collect information 
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on the primary site of mucosal melanomas in our patient population, it is possible that response 
to treatment may have differed depending on anatomic location.  
The distinct biological characteristics of melanoma subtypes are likely to be explained, at least in 
part, by differences in genetic alterations.25,26,27 BRAF gene mutations occur at a much lower rate 
in mucosal melanomas than in cutaneous melanomas without chronic sun damage.25 Conversely, 
gene copy number and structural variations (eg, in c-KIT) are much more common in mucosal 
melanoma than in cutaneous melanoma.26 Patients were not selected for mutational status in our 
analyses; however, the results suggest that nivolumab may be effective in mucosal melanoma 
regardless of the tumor molecular profile, similar to the demonstrated efficacy of nivolumab in 
cutaneous melanoma regardless of BRAF mutation status.28  
In our study population, it is interesting to note that more patients with cutaneous melanoma had 
tumor PD-L1 expression ≥5% than patients with mucosal melanoma. The reasons for this finding 
remain unclear, but one hypothesis is that mucosal melanomas may be less immunogenic due to 
a lower mutational burden.26 Despite differences in the proportion of patients with tumor PD-L1 
expression ≥5%, ORR was similar between subtypes for nivolumab monotherapy and 
combination therapy. In contrast, lower activity in mucosal melanoma was observed across 
treatment groups for patients with tumor PD-L1 expression <5%. However, an ORR of 33.3% 
with nivolumab plus ipilimumab in patients with mucosal melanoma and tumor PD-L1 
expression <5% suggests clinical activity of the combination regardless of PD-L1 status. The 
role of PD-L1 as a biomarker for nivolumab alone or in combination with ipilimumab remains 
unclear in any melanoma subtype, but the availability of mature OS data may help answer this 
question.  
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Poor outcomes have been reported with conventional therapies for mucosal melanoma, and there 
remains a high unmet need for effective systemic treatments for this subtype.12 Due to its rarity, 
mucosal melanoma has not been studied in large, randomized clinical trials. Thus, data 
supporting the efficacy of new systemic therapies is mostly based on anecdotal evidence and 
small retrospective analyses. Imatinib has demonstrated efficacy in patients with mucosal 
melanoma, but treatment is limited to the subset of patients with KIT mutations.14,15  The results 
of our current analyses support prior reports showing an ORR with ipilimumab of 7% to 12% 
and a median PFS of 2.3 to 4.3 months in patients with mucosal melanoma.16,17,18 While there are 
no studies directly comparing agents, the median PFS of 5.9 months and ORR of 37.1% with 
nivolumab plus ipilimumab suggest that this combination may provide a greater outcome in 
patients with mucosal melanoma than previously reported with other therapies. 
In summary, this large, pooled analysis of data from six clinical studies provides evidence for the 
efficacy and safety of anti-PD-1-based therapy in an aggressive melanoma subtype with a very 
poor prognosis. Patients may benefit from anti-PD-1-based therapy regardless of the presence of 
poor prognostic factors, tumor PD-L1 expression, and prior therapy. The results of our analyses, 
pending mature OS data, suggest that nivolumab alone and in combination with ipilimumab are 
promising treatment options for mucosal melanoma. 
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Table 1. Baseline Characteristics of the Patients 
 













Age, years        
     Median (range)  61 (22‒89) 60 (18‒90) 65 (35‒86) 62 (18‒87) 61 (31‒80) 62 (18‒89) 
Age category, No. (%)       
     <65 years  49 (57.0) 412 (62.0) 17 (48.6) 191 (58.6) 24 (66.7) 150 (55.8) 
     ≥65 and <75 years 23 (26.7) 167 (25.1) 8 (22.9) 106 (32.5) 9 (25.0) 81 (30.1) 
     ≥75 years 14 (16.3) 86 (12.9) 10 (28.6) 29 (8.9) 3 (8.3) 38 (14.1) 
Sex, No. (%)       
     Male 42 (48.8) 432 (65.0) 16 (45.7) 219 (67.2) 17 (47.2) 180 (66.9) 
     Female 44 (51.2) 233 (35.0) 19 (54.3) 107 (32.8) 19 (52.8) 89 (33.1) 
ECOG performance status, No. (%)       
     0 57 (66.3) 454 (68.3) 24 (68.6) 253 (77.6) 25 (69.4) 193 (71.7) 
     1 27 (31.4) 209 (31.4) 10 (28.6) 72 (22.1) 11 (30.6) 76 (28.3) 
     2 0 0 1 (2.9)  1 (0.3) 0 0 
     Not reported  2 (2.3) 2 (0.3) 0 0 0 0 
M stage, No. (%)*       
     M0/M1a/M1b 28 (32.6) 240 (36.1) 12 (34.3) 142 (43.6) 16 (44.4) 111 (41.3) 
     M1c 57 (66.3) 409 (61.5) 22 (62.9) 184 (56.4) 19 (52.8) 158 (58.7) 
     Not reported  1 (1.2) 16 (2.4) 1 (2.9) 0 1 (2.8) 0 
LDH, No. (%)       
     ≤ULN  43 (50.0) 399 (60.0) 18 (51.4) 219 (67.2) 19 (52.8) 182 (67.7) 
     >ULN 41 (47.7) 253 (38.0) 17 (48.6) 106 (32.5) 16 (44.4) 86 (32.0) 
     ≤2x ULN 69 (80.2) 576 (86.6) 28 (80.0) 295 (90.5) 31 (86.1) 249 (92.6) 
     >2x ULN 15 (17.4) 76 (11.4) 7 (20.0) 30 (9.2) 4 (11.1) 19 (7.1) 
     Not reported  2 (2.3) 13 (2.0) 0 1 (0.3) 1 (2.8) 1 (0.4) 
History of brain metastases, No. (%)       
     Yes 1 (1.2) 59 (8.9) 3 (8.6) 8 (2.5) 0 11 (4.1) 
     No 84 (97.7) 595 (89.5) 32 (91.4) 318 (97.5) 36 (100) 258 (95.9) 
     Not reported  1 (1.2) 11 (1.7) 0 0 0 0 
BRAF status, No. (%)       
     Mutant  4 (4.7) 151 (22.7) 2 (5.7) 114 (35.0) 4 (11.1) 95 (35.3) 
JCO/2016/679258 
  22 
     Wild-type  79 (91.9) 496 (74.6) 33 (94.3) 212 (65.0) 32 (88.9) 174 (64.7) 
     Not reported  3 (3.5) 18 (2.7) 0 0 0 0 
PD-L1 status, No. (%)**       
    Positive (≥5%) 15 (17.4) 228 (34.3) 10 (28.6) 120 (36.8) 7 (19.4) 121 (45.0) 
    Negative/indeterminate (<5%)   49 (57.0) 299 (45.0) 18 (51.4) 126 (38.7) 21 (58.3) 120 (44.6) 
    Not evaluable/not reported  22 (25.6) 138 (20.8) 7 (20.0) 80 (24.5) 8 (22.2) 28 (10.4) 
Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; ULN, upper limit of normal.  
*Based on cutaneous melanoma criteria. 
**PD-L1 positivity was defined as ≥5% of tumor cells exhibiting cell-surface PD-L1 staining of any intensity in a section containing at least 100 
evaluable tumor cells. 
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Table 2. Best Overall Response   
 













Best overall response, No. (%)  
      Complete response  5 (5.8) 46 (6.9) 1 (2.9) 44 (13.5) 0 7 (2.6) 
      Partial response 15 (17.4) 226 (34.0) 12 (34.3) 153 (46.9) 3 (8.3) 50 (18.6) 
      Stable disease  19 (22.1) 112 (16.8) 7 (20.0) 41 (12.6) 3 (8.3) 67 (24.9) 
      Progressive disease  40 (46.5) 245 (36.8) 11 (31.4) 66 (20.2) 27 (75.0) 120 (44.6) 
      Not evaluable  7 (8.1) 36 (5.4) 4 (11.4) 22 (6.7) 3 (8.3) 25 (9.3) 
Objective response rate, % (95% CI)* 
23.3  
(14.8 to 33.6) 
40.9  
(37.1 to 44.7) 
37.1  
(21.5 to 55.1) 
60.4  
(54.9 to 65.8) 
8.3 
(1.8 to 22.5) 
21.2  
(16.5 to 26.6) 
Time to objective response (months)  
     No. of responders  20 272 13 197 3 57 
     Median (range)  
2.3  
(1.6 to 6.9) 
2.6  
(1.2 to 12.5) 
2.9  
(1.9 to 9.9) 
2.8  
(1.1 to 11.6) 
2.6  
(2.5 to 6.6) 
2.8 
(2.5 to 12.4) 
Duration of response (months) 
     Median (95% CI) NR 22.0 (22.0 to NR) NR (7.6 to NR) NR (13.1 to NR) 2.4 (1.8 to 3.0) NR (8.8 to NR) 
Abbreviations: CI, confidence interval; NR, not reached.  
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Table 3. Treatment-Related AEs That Occurred in at Least 5% of Patients 
Adverse event, No. (%)* 
Nivolumab Monotherapy Combination Therapy 
















3 or 4 
Any treatment-related AE  57 (66.3) 7 (8.1) 508 (76.4) 83 (12.5) 34 (97.1) 14 (40.0) 306 (93.9) 179 (54.9) 
    Fatigue  22 (25.6) 1 (1.2) 188 (28.3) 4 (0.6) 13 (37.1) 1 (2.9) 118 (36.2) 17 (5.2) 
    Diarrhea  13 (15.1) 2 (2.3) 102 (15.3) 7 (1.1) 10 (28.6) 3 (8.6) 144 (44.2) 27 (8.3) 
    Rash  8 (9.3) 2 (2.3) 106 (15.9) 0 9 (25.7) 1 (2.9) 101 (31.0) 11 (3.4) 
    Pruritus  9 (10.5) 0 121 (18.2) 1 (0.2) 8 (22.9) 1 (2.9) 117 (35.9) 6 (1.8) 
    Nausea 7 (8.1) 0 84 (12.6) 0 8 (22.9) 0 81 (24.8) 7 (2.1) 
    Lipase increased  1 (1.2) 0 26 (3.9) 16 (2.4) 6 (17.1) 5 (14.3) 34 (10.4) 26 (8.0) 
    Hypothyroidism  4 (4.7) 0 45 (6.8) 0 6 (17.1) 0 50 (15.3) 1 (0.3) 
    Hyperthyroidism  3 (3.5) 0 19 (2.9) 1 (0.2) 5 (14.3) 1 (2.9) 26 (8.0) 2 (0.6) 
    Decreased appetite  7 (8.1) 0 51 (7.7) 0 5 (14.3) 1 (2.9) 53 (16.3) 3 (0.9) 
    Pyrexia  1 (1.2) 0 36 (5.4) 0 5 (14.3) 1 (2.9) 65 (19.9) 4 (1.2) 
    Thyroiditis  0 0 0 0 4 (11.4) 0 10 (3.1) 1 (0.3) 
    Colitis  7 (1.1) 4 (0.6) 1 (1.2) 1 (1.2) 3 (8.6) 2 (5.7) 46 (14.1) 32 (9.8) 
    Aspartate aminotransferase increased 1 (1.2) 0 26 (3.9) 5 (0.8) 3 (8.6) 2 (5.7) 55 (16.9) 18 (5.5) 
    Maculopapular rash 5 (5.8) 0 28 (4.2) 2 (0.3) 3 (8.6) 1 (2.9) 45 (13.8) 8 (2.5) 
    Dyspnea  2 (2.3) 0 23 (3.5) 1 (0.2) 3 (8.6) 1 (2.9) 31 (9.5) 3 (0.9) 
    Vitiligo  4 (4.7) 0 57 (8.6) 1 (0.2) 3 (8.6) 0 26 (8.0) 0 
    Headache  3 (3.5) 0 36 (5.4) 0 3 (8.6) 0 35 (10.7) 3 (0.9) 
    Alanine aminotransferase increased 0 0 23 (3.5) 8 (1.2) 3 (8.6) 0 61 (18.7) 27 (8.3) 
    Asthenia  8 (9.3)  0 48 (7.2) 1 (0.2) 3 (8.6) 0 32 (9.8) 1 (0.3) 
    Constipation  7 (8.1) 0 39 (5.9) 0 3 (8.6) 0 16 (4.9) 1 (0.3) 
    Vomiting  2 (2.3) 0 39 (5.9) 2 (0.3) 3 (8.6) 0 48 (14.7) 8 (2.5) 
    Amylase increased 0 0 16 (2.4) 5 (0.8) 2 (5.7) 2 (5.7) 20 (6.1) 8 (2.5) 
    Pneumonitis  1 (1.2) 0 12 (1.8) 1 (0.2) 2 (5.7) 1 (2.9) 23 (7.1) 4 (1.2) 
    Anemia  3 (3.5) 0 21 (3.2) 1 (0.2) 2 (5.7) 0 12 (3.7) 2 (0.6) 
    Arthralgia  1 (1.2) 0 53 (8.0) 0 2 (5.7) 0 37 (11.3) 1 (0.3) 
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    Dizziness 1 (1.2) 0 14 (2.1)  0 2 (5.7) 0 19 (5.8) 1 (0.3) 
    Hyperhidrosis 3 (3.5) 0 0 0 2 (5.7) 0 10 (3.1) 0 
    Chills 0 0 19 (2.9) 0 2 (5.7) 0 27 (8.3) 0 
    Pain  0 0 0 0 2 (5.7) 0 5 (1.5) 0 
    Vision blurred  3 (3.5) 0 8 (1.2) 0 2 (5.7) 0 8 (2.5) 0 
    Dry mouth 1 (1.2) 0 22 (3.3) 0 1 (2.9) 0 17 (5.2) 0 
    Hypophysitis  1 (1.2) 0 0 0 1 (2.9) 0 29 (8.9) 5 (1.5) 
    Cough 1 (1.2) 0 29 (4.4) 1 (0.2) 1 (2.9) 0 26 (8.0) 0 
    Weight decreased  3 (3.5) 0 8 (1.2) 1 (0.2) 1 (2.9) 0 20 (6.1) 0 
    Myalgia  2 (2.3) 0 24 (3.6) 0 1 (2.9) 0 19 (5.8) 0 
    Abdominal pain  3 (3.5) 0 27 (4.1) 1 (0.2) 0 0 29 (8.9) 1 (0.3) 
Treatment-related AEs leading to 
discontinuation  
4 (4.7) 2 (2.3) 36 (5.4) 26 (3.9) 9 (25.7) 6 (17.1) 124 (38.0) 101 (31.0) 
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Figure 1. Progression-free survival in patients with (A) mucosal melanoma and (B) cutaneous melanoma who received nivolumab 
alone, combination therapy, or ipilimumab alone. Symbols indicate censored observations. Hazard ratios in (A): 0.61 (95% CI, 0.39 to 
0.96; nivolumab versus ipilimumab; P = 0.116); 0.42 (95% CI, 0.23 to 0.75; combination therapy versus ipilimumab; P = 0.003). 
Hazard ratios in (B): 0.73 (95% CI, 0.61 to 0.87; nivolumab versus ipilimumab; P = 0.04); 0.49 (95% CI, 0.40 to 0.61; combination 
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Figure 2. Waterfall plots showing tumor burden change from baseline in patients with mucosal melanoma who received (A) 
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Figure 3. Subgroup analyses of PFS (A) and ORR (B) for patients with mucosal melanoma. Horizontal bars indicate 95% CIs.  
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(B) Objective response rate  
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Appendix  
 
Table A1. Best Overall Response by PD-L1 Status    
 
Nivolumab Monotherapy Combination Therapy Ipilimumab Monotherapy 
Mucosal Cutaneous Mucosal Cutaneous Mucosal Cutaneous 
PD-L1 expression ≥5%  
Best overall response, No. (%) n=15 n=228 n=10 n=120 n=7 n=121 
      Complete response  2 (13.3) 29 (12.7) 1 (10.0) 12 (10.0) 0 6 (5.0) 
      Partial response 6 (40.0) 98 (43.0) 5 (50.0) 70 (58.3) 1 (14.3) 24 (19.8) 
      Stable disease  4 (26.7) 27 (11.8) 2 (20.0) 9 (7.5) 0 37 (30.6) 
      Progressive disease  3 (20.0) 64 (28.1) 2 (20.0) 25 (20.8) 5 (71.4) 46 (38.0) 
      Not evaluable  0 10 (4.4) 0 4 (3.3) 1 (14.3) 8 (6.6) 
Objective response rate, % (95% CI)* 
53.3  
(26.6 to 78.7) 
55.7  
(49.0 to 62.3) 
60.0  
(26.2 to 87.8) 
68.3  
(59.2 to 76.5) 
14.3 
(0.4 to 57.9) 
24.8 
(17.4 to 33.5) 
PD-L1 expression <5%  
Best overall response, No. (%) n=49 n=299 n=18 n=126 n=21 n=120 
      Complete response  1 (2.0) 12 (4.0) 0 17 (13.5) 0 1 (0.8) 
      Partial response 5 (10.2) 93 (31.1) 6 (33.3) 49 (38.9) 2 (9.5) 22 (18.3) 
      Stable disease  6 (12.2) 48 (16.1) 3 (16.7) 20 (15.9) 1 (4.8) 22 (18.3) 
      Progressive disease  30 (61.2) 121 (40.5) 7 (38.9) 30 (23.8) 18 (85.7) 61 (50.8) 
      Not evaluable  7 (14.3) 25 (8.4) 2 (11.1) 10 (7.9) 0 14 (11.7) 
Objective response rate, % (95% CI)* 
12.2  
(4.6 to 24.8) 
35.1  
(29.7 to 40.8) 
33.3  
(13.3 to 59.0) 
52.4  
(43.3 to 61.3) 
9.5 
(1.2 to 30.4) 
19.2 
(12.6 to 27.4) 
Abbreviation: CI, confidence interval. 
*Proportion of patients with a complete or partial response.  
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Figure A2. Progression-free survival by PD-L1 status in patients with mucosal melanoma.      
(A) PD-L1 Expression ≥5% 
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(B) PD-L1 Expression <5% 
 
 
